STOCK TITAN

Bausch Health Companies Inc. - BHC STOCK NEWS

Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.

With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.

Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.

Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.

Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.

For more information, visit www.bauschhealth.com.

Rhea-AI Summary
Bausch Health Companies Inc. reports Q3 2023 financial results with revenue of $2.24 billion, up 9% YoY. The company received FDA approval for CABTREOTM, the first triple-combination topical treatment for acne. Adjusted EBITDA was $830 million, up 8% YoY. Full-year revenue guidance updated to $8.585 - $8.710 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
-
Rhea-AI Summary
Bausch Health Companies Inc. and Salix Pharmaceuticals announced that the U.S. District Court denied Norwich Pharmaceuticals' motion in their lawsuit against the FDA. The court granted summary judgment in favor of the FDA and Salix. The appeal of the final judgment in another case is pending at the U.S. Court of Appeals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
none
-
Rhea-AI Summary
Bausch Health Companies Inc. has launched the first-ever television ad campaign for APLENZIN, a prescription medication for seasonal affective disorder (SAD). The campaign aims to raise awareness about SAD symptoms and encourage dialogue with healthcare professionals. The ad will run on connected TV throughout the winter months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
none
Rhea-AI Summary
Bausch Health and Ortho Dermatologics announce FDA approval for CABTREO, the first and only triple-combination topical treatment for acne
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
none
-
Rhea-AI Summary
Bausch Health Companies Inc. to release Q3 financial results on Nov. 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
Rhea-AI Summary
Salix Pharmaceuticals releases Liver Health Trends Report, highlighting a 9% increase in chronic liver disease (CLD) and cirrhosis mortality. Staffing shortages and disparities in CLD care are also identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
Rhea-AI Summary
Bausch Health Companies Inc. and Salix Pharmaceuticals partner with Bellamy Young to educate people impacted by hepatic encephalopathy (HE) caused by cirrhosis. Bellamy shares her personal experience to help patients, families, and caregivers understand the disease and overcome stigma. UnderstandingHE.com provides educational tools and resources.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
partnership
-
Rhea-AI Summary
Bausch + Lomb completes acquisition of XIIDRA for $2.5 billion, funded by $1.4 billion senior secured notes and $500 million term B loans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
Rhea-AI Summary
Bausch Health Companies and OraPharma partner with LULAC to educate Hispanic community about gum disease. Gum disease affects 65 million American adults and is more common among Latinos. Partnership includes awareness campaign with patient ambassador Alex Rodriguez. OraPharma to provide educational resources and attend National Health Summit. Treatment option for gum disease is antibiotic ARESTIN®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
none

FAQ

What is the current stock price of Bausch Health Companies (BHC)?

The current stock price of Bausch Health Companies (BHC) is $8.48 as of November 15, 2024.

What is the market cap of Bausch Health Companies (BHC)?

The market cap of Bausch Health Companies (BHC) is approximately 3.2B.

What are the primary areas of focus for Bausch Health?

Bausch Health specializes in eye health, gastroenterology, and dermatology.

How many employees does Bausch Health have?

Bausch Health employs approximately 22,000 people worldwide.

In how many countries does Bausch Health operate?

Bausch Health operates in around 100 countries.

What is Bausch Health's largest revenue-generating segment?

The Bausch + Lomb segment generates the highest revenue for Bausch Health.

What recent product development has Bausch Health achieved?

Bausch Health has made significant progress with Amiselimod, a new treatment for ulcerative colitis.

What financial performance did Bausch Health report for Q1 2024?

Bausch Health reported Q1 2024 revenues of $2.15 billion, an 11% increase from the previous year.

How is Bausch Health protecting its intellectual property?

Bausch Health is actively involved in litigation to defend its intellectual property, particularly for the XIFAXAN® franchise.

Where can I find more information about Bausch Health?

More information is available at www.bauschhealth.com.

What recent public drug plan listings has Bausch Health achieved in Canada?

UCERIS® aerosol foam has been listed in the public drug plans of several Canadian provinces, including Ontario, Quebec, and Alberta.

Who is the brand ambassador for the XIFAXAN® awareness campaign?

Award-winning actor Bellamy Young is the brand ambassador for the XIFAXAN® awareness campaign.

Bausch Health Companies Inc.

NYSE:BHC

BHC Rankings

BHC Stock Data

3.17B
367.80M
11.08%
77.48%
3.27%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
QUEBEC